Liver Steatosis and Dyslipidemia After HCV Eradication by Direct Acting Antiviral Agents Are Synergistic Risks of Atherosclerosis

PLoS ONE - United States
doi 10.1371/journal.pone.0209615
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Frontiers in Medicine
Medicine
2019English

Imaging Findings of Hepatocellular Carcinoma That Developed After HCV Eradication With Direct-Acting Antivirals

Acta Hepatologica Japonica
Hepatology
2019English

Significant Improvement of Glycaemic Control in Diabetic Patients With HCV Infection Responding to Direct-Acting Antiviral Agents

Journal of Medical Virology
VirologyInfectious Diseases
2017English

Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy

Hepatology
MedicineHepatology
2017English

Mathematical Modelling of HCV Infection: What Can It Teach Us in the Era of Direct-Acting Antiviral Agents?

Antiviral Therapy
Infectious DiseasesPharmacology
2012English

Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Clinical Liver Disease
Hepatology
2019English

Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2003English

Two Cases of Hepatocellular Carcinoma Occurring Immediately After Direct-Acting Antiviral Agents Against Hepatitis C Virus

Internal Medicine
Internal MedicineMedicine
2019English

Predictors of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct-Acting Antiviral Treatment: Relationship With Serum Zinc

Journal of Clinical Biochemistry and Nutrition
MedicineNutritionClinical BiochemistryDietetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy